Evidence map›Paper›PMID 41852323›Full record

ArticleHaematologica2026

Different primary thyroid B-cell lymphomas show overlapping mutation profiles, suggesting involvement of a common pathogenic process.

Maria-Myrsini Tzioni, Natsuko Watanabe, Ellen Stelloo, Zi Chen, Adheesh Ghosh, Fangtian Wu, Kiminori Sugino, Koichi Ito, Harma Feitsma, Manabu Fujisawa and 6 more

Abstract read
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Maria-Myrsini TzioniDepartment of Pathology, University of Cambridge, Cambridge.
Natsuko WatanabeDepartment of Internal Medicine, Ito Hospital, Tokyo.
Ellen StellooCergentis BV, Utrecht.
Zi ChenDepartment of Pathology, University of Cambridge, Cambridge.
Adheesh GhoshCancer Institute, University College London, London.
Fangtian WuDepartment of Pathology, University of Cambridge, Cambridge.
Kiminori SuginoDepartment of Surgery, Ito Hospital, Tokyo.
Koichi ItoDepartment of Surgery, Ito Hospital, Tokyo.
Harma FeitsmaCergentis BV, Utrecht.
Manabu FujisawaDepartment of Hematology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan; Centre for Lymphoid Cancer department, BC Cancer, Vancouver, British Columbia.
Mamiko Sakata-YanagimotoDepartment of Hematology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan; Department of Hematology, University of Tsukuba Hospital, Ibaraki, Japan; Division of Advanced Hemato-Oncology, Transborder Medical Research Center, University of Tsukuba, Ibaraki.
Lívia Rásó-BarnettThe Haematopathology and Oncology Diagnostic Service, Addenbrookes Hospital, Cambridge.
Teresa MarafiotiCancer Institute, University College London, London, United Kingdom; Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London.
Ayoma D AttygalleDepartment of Histopathology, The Royal Marsden Hospital, London.
Andrew WotherspoonDepartment of Histopathology, The Royal Marsden Hospital, London.
Ming-Qing DuDepartment of Pathology, University of Cambridge, Cambridge. mqd20@cam.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary thyroid lymphomas commonly originate from a background of Hashimoto's thyroiditis and comprise largely extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Thyroid EMZL harbors a distinct mutation profile, but whether this discriminates them from thyroid FL and DLBCL is unknown. To investigate this, we have examined 42 EMZL (11 BCL6-translocation [tr]+ve), 21 FL (5 BCL2-tr+ve, 10 BCL6-tr+ve, 1 both BCL2/BCL6-tr+ve) and 34 DLBCL of the thyroid. Targeted next generation sequencing revealed a remarkable overlap in the mutation profile among thyroid EMZL, BCL2-tr-ve FL and DLBCL, all showing frequent mutations in TET2, IGLL5, TNFRSF14, CD274, GNA13, FAS, KLF2 and TNFAIP3. In contrast, BCL2-tr+ve FL of the thyroid showed frequent BCL2, KMT2D, CREBBP, EZH2, but not TET2 and CD274 mutations. Genomic analysis of BCL6 translocation by targeted locus capture next generation sequencing showed different genomic configurations between thyroid FL and EMZL. In thyroid FL, the majority of BCL6 translocations placed its coding exons under the transcriptional control of the IGH switch region super-enhancer or its partner genes, potentially resulting in BCL6 constitutive expression. In contrast, the majority of BCL6 translocations in thyroid EMZL juxtaposed the BCL6 gene to the IGHJ/D region without encompassing the Eμ enhancer or its partner genes in an opposite orientation, thus less likely to lead to constitutive BCL6 transactivation. The above genetic changes likely dysregulate B-cell maturation and peripheral tolerance, thus offer significant molecular insights into the pathogenesis of thyroid lymphomas, particularly underpinning autoimmunity in the lymphomagenesis and potentially explaining the overlap in histopathology between EMZL and FL.

Indexed as

Lymphoma, B-CellMutationThyroid NeoplasmsHigh-Throughput Nucleotide SequencingHumansTranslocation, Genetic

Identifiers

PMID41852323
PMCPMC13628072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.